C-SD0WCleara
peptide therapeutics, impaired-p53 targeting, apoptosis
clearingbiologic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-SD0W
C-SD0WC-SD0Wpeptide therapeutics, impaired-p53 targeting, apoptosis
0-100 chain-logic scale · 15 dimensions · scored on public evidence
8th Digital Strategy & Innovation for Medical Affairs | Nicholas Sarlis, MD, PhD, FACP LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to Linked … egistered and look forward to becoming conversant with the latest trends in the application of digital technologies (including AI/ML and novel data analytics, 'packaging' and delivery solutions) in Medical and Scientific Affairs across all functions (Med Comms; key external expert engagement; educational initiatives; HEOR; asset positioning across the competitive medical/ market landscape; lifecycle management optimization, etc.). https://lnkd.in/eJtVvagY #medicalaffairs #dig
Agenda | Becker’s Healthcare 16th Annual Meeting 2026 | April 13–16 Toggle navigation Home Agenda & Speakers • Agenda • Featured Speakers • Full Speaker Lineup • AI Summit • Academic Medical Center Leadership Forum • Clinical Leadership Forum • Workforce Forum Exhibitors / Sponsors • Exhibitors & Sponsors • Exhibitor & Sponsor Portal • Event Prospectus Plan your experience • Hotel and Travel • Download the Mobile App • Credits • Marketing Materials • Personalize Your Event Experience Registration Apply for Complimentary Participation Your Personal Schedule Agenda DISRUPTION & I … Effective Delivery 01. Louise Whitfield Carnegie Exceptional Healthcare Leader Award Ceremony 01. Margin, Mission + Market Pressure: CEO + CFO Straight Talk 01. Martin Makary, MD, Commissioner, Food and Drug Administration 01. Navigating Hard Decisions After Reimbursement Declines 01. Navigating Healthcare’s Next Era: Strategies for Growth and Resilience 01. Peter McCanna, CEO at Baylor Scott & White Health & Steve Mackin, President and CEO at Mercy 01. Rob Allen, CE … n 3:58 PM - 4:05 PM 01. Louise Whitfield Carnegie Exceptional Healthcare Leader Award Ceremony 4:10 PM - 5:00 PM 01. Celebrity Keynote - Fernando Mendoza 5:00 PM - 6:00 PM Happy Hour in the Exhibit Hall Time Name 6:00 AM - 6:00 PM Enhanced Security 7:30 AM - 8:30 AM Continental Breakfast in the Exhibit Hall & Registration Opens 7:30 AM - 6:00 PM Exhibit Hall Hours 8:00 AM - 1:00 PM Transform Hospital Operations Summit: Enterprise Intelligence in Action 8:30 AM - 9:10 AM 0
%PDF-1.7 %���� 270 0 obj >stream h��]o���SxU8(��7���يO\$q�4A�XIk{ѵ�J��Ϸ�!%Yvd'm�����v8$gș��UR )�4T +����T{�%�� �D����z*%�1�j% ˕���kh,e� �_9ᨏR^8 _����+n/��$�R�H�h%��vMEJE w&M����d��15��%���]�?���?T�a�g���#��h� �Ln��6����c�0�$K���M�9� � �ݔ��h��%�%��b����mZT�"^���Z�����Ұ��ּ�� 7�el��%tdZ�l��u(�g�${��z�J�Y�"�2'�u���$/�� ��] %�@˩K�Nx�>ixNOH���*�U�i��O+�$��ii�b?h M0쇏�D�~����-����JXU�iG(8xT(L�I�D��,��� �;� d��%�%���.GBԂ�e?(t(��zr6� �Bϕ�G�� i/"�_La�p�e?ht/=�QR�D$+��d?JM�!�J#�K�A�z�Z�9�g?JO �J�5���"��ԋf� ��Qt�ɏ_~)���u�~�� Y D$�����|�Qk��YV���E�ͬ���t … 25-04-02T09:07:32-04:00 2025-04-02T09:07:32-04:00 pdfplot17.hdi 17.00.154.00000 application/pdf 11x17_vert endstream endobj 12 0 obj >/AcroForm 102 0 R/Metadata 2 0 R/OCProperties >/OCGs[103 0 R 104 0 R 105 0 R 106 0 R 107 0 R 108 0 R 109 0 R 110 0 R 111 0 R 112 0 R 113 0 R 114 0 R 115 0 R 116 0 R 117 0 R 118 0 R 119 0 R]>>/Outlines 204 0 R/PageLabels >]>>/PageLayout/SinglePage/PageMode/UseOutlines/Pages 9 0 R/Type/Catalog>> endobj 24 0 obj >/Filter/FlateDecode/Length 98395/L … 25-04-03T09:06:08-04:00 2025-04-03T09:06:08-04:00 pdfplot17.hdi 17.00.154.00000 application/pdf 11x17_vert endstream endobj 29 0 obj >/BBox[0.0 -3.89999 88.704 12.48]/Filter/FlateDecode/FormType 1/Length 103/Matrix[1.0 0.0 0.0 1.0 303.612 668.408]/Resources >/ProcSet[/PDF/Text]>>/Subtype/Form/Type/XObject>>stream H�$LI �0��9��� �xA1 ��� bgD���*�,��P (��e�T�a���Y�L2�95�,]���&� ��}6/kCR8w��7��O��T+��] � �6� endstream endobj 30 0 obj >/BBox[0.0 -3.89999 31.332 12.48]/Fil
Exhibitors Skip to main content Toggle navigation Search Home Exhibitors Home Exhibitors Exhibitors Type here to filter the list All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # Sort by Booth Sort by Company A 628 Abbott 435 Accio Data 211 Accurate Biometrics 319 Accurate Source 331 AccuSearch 130 Affirm 419 AMS Inform 431 Argyle 126 Astute Public Records B 235 BackChecked 215 Baxter Research 115 Berg Consulting 125 BIS 532 BRB Publications C 100 Chetu, Inc. 518 Cleara 624 ClearStar 335 Convergence Research 103 Corporate Research and Investigations Limited 519 CRAzoom 322 CRI Criminal
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Instagram Instagram Log In Sign Up Close Never miss a post from agiletestingalliance Sign up for Instagram to stay in the loop. Sign up Log in agiletestingalliance • Follow More options agiletestingalliance 12w We sincerely thank QAGuides for being our 𝐂𝐨𝐦𝐦𝐮𝐧𝐢𝐭𝐲 𝐏𝐚𝐫𝐭𝐧𝐞𝐫 for #AiTestFest2026 . #ATATF2026 , the 2nd Edition of the AiTestFest, will be held on, Date : 9th May 2026 Venue : Nagarro Software Pvt Ltd – Plot 6B, Sub. Major Laxmi Chand Rd, Maruti Udyog, Sector 18, Sarhol, Gurugram, Haryana 122015 The theme for #ATAITF2026 is "𝐓𝐑𝐔𝐒𝐓, 𝐓𝐄𝐒𝐓, 𝐓𝐑𝐀𝐍𝐒𝐅𝐎𝐑𝐌 —
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Pipeline | Cleara Biotech Skip to content Toggle Navigation Home Company About Team Board History Business progress Contact Focus Impaired-p53 in cancer Programs Pipeline Careers Toggle Navigation Home Company About Team Board History Business progress Contact Focus Impaired-p53 in cancer Programs Pipeline Careers Pipeline Pipeline Through academic collaborations and its own research, Cleara currently has the following compounds against senescence-driven pathologies in its research pipeline: Copyright © Cleara Biotech | Legal Information | Data Privacy Copyright © Cleara Biotech Legal Informat
Attendee List About About the Event Attendee List Social Media Get Involved Online Learning & Podcasts Media Gallery Testimonials Key Contacts FAQ Agenda Search Agenda Event-at-a-Glance Conference Tracks Symposia Workshops FAIR Data Hackathon Plenary Keynotes Interactive Discussions Intelligence Briefs Speaker Biographies Brochures Networking Venture/Partner Event Sponsorship Attendee Demographics + Features Sponsorship Opportunities Current Sponsors Sponsorship Prospectus Current Exhibitors/Floorplan Re-sign Floorplan Exhibit Services / Schedule Lead Gen Opportunities FAQs Innovation Show … wcase Awards Innovative Practices Awards Best of Show Awards Emerging Innovator Award Travel Press Newsroom Media Partners Press Pass Podcast Posters Poster Information Poster Titles Register Individual Pricing Group Pricing On-Demand Pricing Exhibit Hall & Keynote Pass 2026 Attendee List Join the growing list of your peers for 22nd Annual Bio-IT World Conference & Expo (Partial List Only) --> - Attending in person - Attending virtually Compan
Cleara Biotech Skip to content Toggle Navigation Home Company About Team Board History Business progress Contact Focus Impaired-p53 in cancer Programs Pipeline Careers Toggle Navigation Home Company About Team Board History Business progress Contact Focus Impaired-p53 in cancer Programs Pipeline Careers Home Improving lives through peptide-based clearance of p53-impaired cells. That’s our mission Cleara Biotech is a biopharmaceutical research and development (R&D) company focused on developing peptide-based therapies against cancer and chronic diseases. Our lead program focuses on generati
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Emissions Reductions Under Pollution Reduction Proposals in the 111th U.S. Congress | World Resources Institute Skip to main content Accessibility World Resources Institute Making Big Ideas Happen Main navigation Research Recently Published Reach an Expert Our Standards Permissions & Licensing All Publications Data Initiatives Insights Click to see more Donate Donate Donate Quick Links Quick Links News Resource Library Experts Events Careers Donate Click to see more Main navigation Research Data Initiatives Insights Footer menu - secondary Our Work Regions Africa Asia Europe Latin America … ill achieve emissions reductions through the passage and implementation of each proposal. Reductions that would require additional congressional action to be realized are not included in the analysis. Estimates of Total Net GHG Emissions and Emissions Reductions Achieved by Pollution Reduction Proposals in the 111th Congress, 2005-2050 presents a table of total net GHG reductions that could be achieved by these proposals for selected years. Download the PDF above for a full d
TIAA was honored to partner with the Big Ten Conference Equality Coalition through the Big Life Series. Most recently, we retraced the path of the historic 1965 Selma to Montgomery march—an unforgettable experience that brought history to life and reinforced the importance of legacy, learning, and meaningful action. #BigTen #TIAAProud | TIAA
Cleara Biotech senolytic candidate FOXO4-DRI Donate Login About Mission Board of Directors Scientific Advisory Board Team Annual Reports Contact Research Supported Projects Investments Publications Education Summer Scholars Post-Baccalaureate Host Lab Signup News Outlet Investor Network About Join Reports Advocacy Video Initiatives Engaging the Press Crowdfunding Sponsored Projects Advocacy Topics A4LI Resources Rejuvenation Roadmap Infographics Longevity Topics Find Longevity Events EARD Conference Archive Get Involved Donate Be a Lifespan Hero Hall of Heroes Join the Lifespan Alliance Crypto
STR_ERROR_PAGE_TITLE INDEX_COOKIE_WARNING STR_LOGOUT
Cleara Biotech BV - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 20 Oct 2025 Cleara Biotech BV Startups | Holding Company | 2018 | Netherlands | 10-50 | www.clearabiotech.com Startups | Holding Company | 2018 | Netherlands | 10-50 | www.clearabiotech.com Last update 20 Oct 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Neoplasms Other Diseases Digestive System Disorders Chemical drugs Synthetic peptide Disease domain score A glimpse into the focused … th participation from Curie Capital B.V., ROM Utrecht Region and Longevity Tech Fund. The proceeds will be used to progress Cleara’s compounds toward clinical development and further build the Company’s developmental pipeline and management team. Cleara has optimized two lead developmental candidates, CL04177 and CL04183, that can eliminate scarred cancer cells found in several late-stage cancers and chronic diseases in humans. The Company is aiming to develop precision medic … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Watercolor Tutorial For Beginners | you can NEVER have too many socks… especially on cleara
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Cleara - 2026 Company Profile, Team, Funding & Competitors - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Investment Banks Corpor
AI & Deep Tech VC Funds — Page 5 | Waveup Copilot Assisted fundraising Log in | Sign up Home Guides Assets Investors VC funds Tailored lists Favorites Academy Privacy policy Terms of Use Privacy Policy Help center Return to waveup.com Sector AI & Deep Tech VC Funds Venture capital funds investing in artificial intelligence, machine learning, deep learning, and advanced technology startups. Browse fund profiles, check sizes, and investment focus areas. Fund profile Geography Check Fund website Apollo Ventures Apollo Health Ventures is a transatlantic venture capital firm founded in 2016 … and led by Managing Director Nils Regge, the firm's singular mission is to fund and co-build companies that target the root causes of aging and age-related diseases. Apollo focuses on breakthrough science in Alzheimer's disease, heart disease, cancer, sarcopenia, and frailty — with the ultimate goal of extending healthy human lifespan. The firm takes an active company-building role, frequently co-founding portfolio companies alongside scientists and entrepreneurs. Ap … tes and Europe, reflecting the firm's transatlantic orientation and its Bio Fund I structure. Apollo Health Ventures differentiates itself through its company-building model: the team does not passively invest in existing longevity companies but actively participates in their creation, recruiting scientists, shaping research strategy, and guiding early clinical positioning. This founder-in-residence approach concentrates portfolio expertise in a narrow therapeutic categor … on support available as companies grow. In 2023, they launched HEARTFELT, a new fund focused on continuing early-stage investments while managing their existing portfolio. With a hands-on approach, APX offers not just capital but also guidance on sales, operations, and strategic partnerships. Their network of experienced investors and successful entrepreneurs plays a key role in helping startups scale. $1M-$3M $10M-$50M +2 Website Aqua Spark Aqua-Spark, based in the Netherlan … Website Aqua Spark Aqua-Spark, based in the Netherlands, is a global investment fund dedicated to sustainable aquaculture. Founded in 2013 by Mike Velings and Amy Novogratz, the fund aims to transform the aquaculture industry by promoting environmental and social sustainability alongside financial returns. Aqua-Spark's mission is to make the
Cleara Biotech Stock Price, Funding, Valuation, Revenue & Financial Statements Technology Vendors Recent Research Newsletter Media Support Login Who We Serve Function Corporate Strategy Corporate Venture Capital Venture Capital IT Corporate Innovation How VCs Use CB Insights Go to the video gallery → Industries Consumer & Retail Tech Insurance Healthcare Industrials Financial Services Professional Services Professional Services Learn More → Success Stories How We Help Understand Tech Markets Anticipate Competitor Strategy Determine Tech Strategy Connect with Tech Vendors & Partners … /2022 Seed VC - II $2.5M Apollo Health Ventures , Curie Capital , Longevitytech.fund , and ROM Utrecht Region $XXM 0 FY undefined 4 7/6/2018 Seed VC Subscribe to see more $XXM 0 FY undefined 10 1/1/2018 Pre-Seed Subscribe to see more $XXM 0 FY undefined 10 Other Investors Subscribe to see more $XXM 0 FY undefined 10 Date 9/28/2022 7/6/2018 1/1/2018 Round Seed VC - II Seed VC Pre-Seed Other Investors Amount $2.5M Investors Apollo Health Ventures , Curie Capital , Longevitytech … s Amount $2.5M Investors Apollo Health Ventures , Curie Capital , Longevitytech.fund , and ROM Utrecht Region Subscribe to see more Subscribe to see more Subscribe to see more Valuation $XXM $XXM $XXM $XXM Revenue 0 FY undefined 0 FY undefined 0 FY undefined 0 FY undefined Sources 4 10 10 10 Learn more by requesting a demo Cleara Biotech Investors 7 Investors Cleara Biotech has 7 investors . Curie Capital invested in Cleara Biotech's Seed VC - II funding round . First fu … 1 Seed VC - II Venture Capital Netherlands 00/00/0000 00/00/0000 Longevitytech.fund Subscribe to see more Venture Capital Czech Republic 00/00/0000 00/00/0000 Apollo Health Ventures Subscribe to see more Venture Capital Germany 00/00/0000 00/00/0000 ROM Utrecht Region Subscribe to see more Asset/Investment Management Netherlands 00/00/0000 00/00/0000 Apollo Health Ventures Subscribe to see more Venture Capital Germany First funding 9/28/2022 00/00/0000 00/00/0000 00/00/0000 … 0/00/0000 00/00/0000 00/00/0000 00/00/0000 Investor Curie Capital Longevitytech.fund Apollo Health Ventures ROM Utrecht Region Apollo Health Ventures Rounds 1 Seed VC - II Subscribe to see more Subscribe to see more Subscribe to see more Subscribe to see more Board Seats Type Venture Capital Venture Capital Venture Capital Asset/Investment Manage
Cleara Biotech Raises $2.5 Million in Seed Financing to Advance FOXO4- Therapeutics Pipeline for Treating Cancer and Chronic Diseases - Curie Capital --> --> --> --> --> --> --> --> --> --> --> --> --> Home Approach Portfolio Team News Contact Select Page News Cleara Biotech Raises $2.5 Million in Seed Financing to Advance FOXO4- Therapeutics Pipeline for Treating Cancer and Chronic Diseases September 21, 2022 Cleara_PressRelease_Sep222022 Back to news Our other news Stay informed about the latest updates from Curie Capital and the ongoing activities within our portfolio companies. News Jun 25 … ew investors Kurma Partners (Eurazeo Group) and the European Innovation Council Fund (EICF) join the A2 syndicate led by Dutch... KNOW MORE News Apr 14, 2026 Laigo Bio strengthens team with Chief Scientific Officer and Scientific Advisory Board appointments Richard C.A. Sainson, PhD, experienced R&D executive and scientific leader with demonstrated track record, appointed Chief... KNOW MORE News Apr 4, 2026 Laigo Bio completes final close of oversubscribed seed financing
Curie Capital — Portfolio & Investments | Fundable fundable. DATA PLATFORM Dashboard Companies People Investment Firms Angels & Partners COLLECTIONS Lists Saved Searches Hiring Lists WORKFLOWS Deal Alerts Integrations API + Credits Toggle Sidebar Overview Highlights Investments Team Curie Capital Investments 14 Lead Investments 1 Curie Capital is a life science focused venture capital firm founded in 2018. It is a new and dynamic investment fund with a personal touch. Curie Capital is based in Amsterdam and invests in early stage companies with talented teams and exciting science and t
%PDF-1.7 %���� 1 0 obj >/Metadata 75 0 R/ViewerPreferences 76 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 612 792] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��]ms�8�����|�Җ�_�\�r go�f6����\����,V�K���~��i������Te���K����x��؈��7?_�����Tl�Ĭڜ��q~y)��z�* B��K%B�����M����Ql^�z����7縷QF����+i> )�4ȣH�a$����|�O Sqך�w�,s�����?f��j~�g� [1׳�ţ�|�w�J���y�C���8̃,�����) �D$�Y@�@ЧU�.7�{���>t��u����Km��Z�U HŹ�3O�X� �Zn�������� ��ǵQ��(D#�Ne�h!�WF�h3V��b�x����M��/Q�Aw�o�����B������u�R�*I
Explore ways to participate at this year's BIO CEO & Investor Conference | Peter de Keizer LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree t … ematological malignancies. While these developments are promising, the clinical application of senolytic therapies remains in the early stages. Ongoing and future clinical trials will be crucial in determining the safety and efficacy of these treatments in humans. Like Reply 1 Reaction drs. Léon Strijthagen 1y Report this comment WANNEER KOMT HET ANTI VEROUDERINGS MEDICIJN OP DE MARKT? https://www.umcutrecht.nl/nieuws/gezonder-oud-door-aanpak-roestcellen Like Reply 1&nbs … ciences Frazier Life Sciences Andera Partners Deep Track Capital Bayern Kapital Fund+ HTGF | High-Tech Gründerfonds OCCIDENT Seventure Partners Dominik Schumacher Lorence Kim Patrick Heron https://lnkd.in/eND7KX6f Germany: Tubulis raises €308m Series C to expand clinical development of lead ADC candidate investorsinhealthcare.com 34 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Andrew Lloyd & Associates 1,619 followers 8mo Edited Report thi
Cleara - Curie Capital --> --> --> --> --> --> --> --> --> --> --> --> --> Home Approach Portfolio Team News Contact Select Page Cleara Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings. Our other portfolio companies We work closely with our portfolio companies to review transactions that leverage operational and management expertise. View full portfolio SFDR © 2024 Curie Capital. All rights reserved. | Dez
Homepage - Cleara You are using an outdated browser. Please upgrade your browser to improve your experience. Our Data Solutions Company Contact Solutions Our Data Technology Industries Employment Tenant Screeners Volunteers Company About Cleara The Cleara Difference Partners Associations Leadership Contact Customer Support Resource Library Industry-Leading Background Screening Data Cleara is a decision-ready background screening data platform built to ensure accuracy and reduce operational and reputational risk for background screeners. Get started A better standard for background screening da
Cleara Biotech B.V. - [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News AMD, Dell & Univ Cambridge Launch UK AI Innovation Lab Caszyme: WiFIX Consortium Awarded €1m Eurostars Grant GSK to Acquire Nuvalent for $10.6b in Cash Merck Appoints Two Life Sciences Leadership Team Members Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Roche and Nurix: up to $2.3b Agreement for BTK Degrader AMD Commits up to £2b to Accelerate AI in UK DaltonTx Launches Platform and Partners with Sygnat … to Biosciences and DaltonTx: AI-Driven Collaboration » More News! » Submit your News! Upcoming Events UBS Life Sciences Conference 2026 London Metabolomics 2026 Buenos Aires BIO 2026 San Diego (BIO International Convention) TD Cowen’s Tools/Dx Revolution Conference 2026 Dana Point Truist Securities Healthcare Disruptors & Digital Health Conference 2026 New York LSI Asia ’26 Emerging MedTech Summit 2026 Singapore Longevity Summit Dublin 2026 European Spatial Comput … f America Global Healthcare Conference London 2026 » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Orlando Oliveira Succeeds Dario Eklund as CEO of Santhera Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Evotec Nominates Dieter Weinand as Supervisory Board Chair Santhera Appoints Marc Clausse as Chief Commercial Officer Fujifilm Biotechnologies Appoints Christiane Bardroff as CBO Camil … n Bulling Joins ProBioGen as Chief Operating Officer » More News! » Submit your News! Financings & Acquisitions Ona Therapeutics Raises $86.6mSeries B to Advance ADCs Olix Pharma Secures KRW110b Investment from BOLD and Weiss T-Curx GmbH Acquires Pantherna Therapeutics GmbH Genovis Acquires KPL ApS for DKK30.5m Upfront plus Earn-outs Lilly to Acquire LimmaTech Biologics for up to $780m in Cash InSphero Acquires PhenoVista Biosciences to Expand in US Lauxera Capita … henoVista Biosciences to Expand in US Lauxera Capital Partners Closes Growth II Fund at €520m Metis TechBio: $270m IPO at Hong Kong Stock Exchange NanoStruct Closes €2.6m Seed Round Led by HTGF et al. Roche to Acquire PathAI for up to $1.05b » More News! » Submit your News! Collaborations & Licensing Roche and Nurix: up to $2.3b Agree
Cleara closes $2.5m seed financing to advance senotherapeutics Skip to content News Data Podcast Clinics News Data Podcast Clinics Search Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Advertise NEWSLETTER News Data Podcast Clinics News Data Podcast Clinics Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire About Contact About Contact Advertise nEWSLETTER Search Search Next Health opens flagship ... … with participation from Curie Capital BV, ROM Utrecht Region and Longevity Tech Fund. The proceeds will be used to progress Cleara’s compounds toward clinical development and further build the Utrecht-based biotech’s developmental pipeline and management team. Longevity.Technology: Cleara has optimised two lead developmental candidates, CL04177 and CL04183, that can eliminate scarred cancer cells found in several late-stage cancers and chronic diseases in humans. The co
CLEARA Biotech's innovative approach to cellular senescence | Nicholas Sarlis, MD, PhD, FACP posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to
Cleara Biotech B.V. - [LSBNL] Life-Sciences-Benelux.com - The Benelux Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News AMD, Dell & Univ Cambridge Launch UK AI Innovation Lab AMD Commits up to £2b to Accelerate AI in UK Ona Therapeutics Raises $86.6mSeries B to Advance ADCs Lundbeck & Cradle Partner for AI-based Brain Disorder R&D AMD Silo AI and Delphyr AI PArtner for AI in Clinical Care Qiagen Announces Collaboration with Nvidia at Bio-IT World Scarlet Therapeutics Closes £3.2m Seed Round Led by Eos CellCentric Announces $220m Ser … 5b Tibeay Biosciences Raises €35m Round Led by Athos » More News! » Submit your News! Upcoming Events Metabolomics 2026 Buenos Aires BIO 2026 San Diego (BIO International Convention) EUROMAR 2026 Gothenburg (Göteborg) bio:cap Investival 2027 Berlin (BioCap 2027) World Health Expo Osaka 2026 (WHX Osaka 2026) ISSCR 2026 Montréal DxPx U.S. Conference 2026 Anaheim ADLM 2026 Annual Meeting & Clinical Lab Expo Anaheim IMSC 2026 Lyon European Conference on Computational … 2026 Marseille Biotech Showcase 2027 San Francisco » More Events! » Submit your Event! Management Appointments Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Bruker Appoints Qiagen CEO Thierry Bernard as Board Director Qiagen Appoints Mark Stevenson to Supervisory Board Pharming Group Appoints Kenneth Lynard as CFO Carmen Berger to Head Medica and Compamed Trade Fairs Julius Clinical Welcomes Bassem Saleh as CEO BIO Deutschland Elects Roland Sackers … ectorY Therapeutics Appoints Jessica Atkinson as CBO » More News! » Submit your News! Financings & Acquisitions Ona Therapeutics Raises $86.6mSeries B to Advance ADCs CellCentric Announces $220m Series D Led by Venrock UCB to Acquire Candid Therapeutics for up $2.2b UCB Has Acquired the IMIDomics’ Patient Insight Business Coultreon’s $125m Series A Is Led by Sofinnova Investments CARB-X Awards Funding to AdJane to Advance Gonorrhea Vaccine UCB to Acquire Neurona T … os Adcendo Closes $75m Series C Led by Jeito Capital » More News! » Submit your News! Collaborations & Licensing Lundbeck & Cradle Partner for AI-based Brain Disorder R&D Hansa Biopharma: €115m Licensing Agreement with SERB UCB Licenses Bispecific TCE Antibody from Antengene Bayer & Cradle Bio Announce 3-year Strategic Collaboration V
The European Research Institute for the Biology of Ageing (ERIBA) launches a biotech company Cleara Biotech BV (CLEARA) – Nederlandse Vereniging voor Verouderings Onderzoek Ga naar inhoud Home Over DuSRA Missie Bestuurspagina Young society Instituten Onderzoek Papers Onderwijs De Internationale Master Vitality and Ageing Middelbaar onderwijs – Profielwerkstuk Gratis mini-cursus ‘Vitaal en gezond ouder worden’ Contact Contactpagina Lid worden? VOILA Home Ambitie VOILA Lectures VOILA staff Onderzoek VOILA NEUROMET Team NEUROMET SMARTage Team SMARTage VOILA Team VOILA Partners Contact VOILA … mate goal is to discover the basic mechanisms underlying the ageing process and apply this knowledge to improve health. By initiating Cleara, we hope that such knowledge can be applied to society in the most effective manner”. – Gerald de Haan, Scientific Director ERIBA The UMCG is one of the largest hospitals in the world and employs almost 13.000 people. The UMCG is the beating heart of the Healthy Ageing Campus which is part of Campus Groningen. Joyce_Vriezen 2018-12-17T11
Cleara Biotech | Research profile | Nature Index Skip to main content Advertisement Search Main Navigation Home News News home News Comment Data insights Dataviz Careers Q+A Archive Current Index Institution rankings Institution benchmarking Institution collaboration Country/territory rankings Country/territory benchmarking Country/territory collaboration Data visualizations Articles Research highlights Topics Topic explorer Nature Index topics Leading institutions by topic Leading countries/territories by topic Research leaders Research leaders home 2026 Research Leaders 2025 Research Leaders … Share for each subject. Leading research topics In the Current Index (12-month rolling window), Cleara Biotech published the most articles in these research topics. Learn more about Nature Research Intelligence Topics . Topics Count Share Oncology and Carcinogenesis 1 0.05 View all topics Share output for the past 5 years Subject area or journal group 2021 2022 2023 2024 2025 Overall 0 0 0 0 0 Health sciences 0 0 0 0 0 Institution benchmarking Turn complex research questions … nt bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more. Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions. Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises. Explore course catalogues and workshop agendas, enquire abo … 0,000 active job seekers per month that you can target directly with your role. Application response rates have increased by 28% on average over 2022 averages. Advertise your job roles on Nature Careers Recruitment subscriptions Building your employer brand Latest supplements Nature Index 2026 Chemistry Chemistry research is undergoing a period of transformation, driven by new technologies and mounting environmental pressures. In this supplement, we explore the trends behind
Cleara Biotech B.V. - Executive Leadership | The Org Platform Enrich Pricing Log in Sign up Cleara Biotech B.V. Teams Executive Leadership Unverified Executive Leadership 2 people · 0 jobs This department provides strategic direction and governance for the organization. People ( 2 ) Marianne Mertens Board Director Mariette van der Velden-Roesink Member Of The Supervisory Board Jobs ( 0 ) No jobs in this team Other teams View all teams Research and Development 2 people · 0 jobs MT Company About Contact Blog Business Solutions Trust Pricing Directory Companies People Features Employer Branding
Cleara Biotech Raises $2.5 Million in Seed Financing to Advance FOXO4-Therapeutics Pipeline for Treating Cancer and Chronic Diseases | Han de Groot LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By … t Our biotech vc firm Curie Capital BV , Apollo Health Ventures , Longevitytech.fund and ROM Utrecht Region have closed an investment in Cleara Biotech B.V. Cleara Biotech B.V. under scientific leadership of Dr. Peter de Keizer , develops drugs targeting ‘scarred cellular’ senescence. It will use the new funds to advance its promising lead compounds against late-stage cancer and chronic diseases. Cleara has appointed Dr. Angelos M. Stergiou, MD,ScD hc as its Board of Director
Contact | Cleara Biotech Skip to content Toggle Navigation Home Company About Team Board History Business progress Contact Focus Impaired-p53 in cancer Programs Pipeline Careers Toggle Navigation Home Company About Team Board History Business progress Contact Focus Impaired-p53 in cancer Programs Pipeline Careers Contact Please fill out the form in order to contact us. Name * E-mail Address * Subject * Message * By using this form you agree with the storage and handling of your data by this website. × Copyright © Cleara Biotech | Legal Information | Data Privacy Copyright © Cleara Biotec
CLEARA Biotech Appoints Nicholas J. Sarlis, MD, PhD as Chief Medical Officer and Head of Clinical Development - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business CLEARA Biotech Appoints Nicholas J. Sarlis, MD, PhD as Chief Medical Officer and Head of Clinical Development February 22, 2023 | 4 min read Twitter LinkedIn Facebook Email Print CLEARA Biotech B.V. (“Cleara” or the “Company”) today announced that immunotherapy and oncology expert Dr. Nichola … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Cleara Biotech Raises $2.5 Million in Seed Financing to Advance FOXO4-Therapeutics Pipeline for Treating Cancer and Chronic Diseases - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing De … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Cleara Biotech Raises $2.5 Million in Seed Financing to Advance FOXO4-Therapeutics Pipeline for Treating Cancer and Chronic Diseases September 28, 2022 | 4 min read Twitter LinkedIn Facebook Email Print CLEARA Biotech B.V. announced that it closed a $2.5 million seed financing round earlier in the year, led by Apollo He … th participation from Curie Capital B.V., ROM Utrecht Region and Longevity Tech Fund. Company Also Appoints Seasoned Industry Executive, Dr. Angelos Stergiou, as Board of Directors Chairman in Advance of Lead Program Entering the Clinic UTRECHT, Netherlands--( BUSINESS WIRE )-- CLEARA Biotech B.V. (“Cleara” or the “Company”), a preclinical-stage biotechnology company focused on developing innovative, proprietary therapies for treating different pathologies of “scarred cellula … th participation from Curie Capital B.V., ROM Utrecht Region and Longevity Tech Fund. The proceeds will be used to progress Cleara’s compounds toward clinical development and further build the Company’s developmental pipeline and management team. Cleara has optimized two lead developmental candidates, CL04177 and CL04183, that can eliminate scarred cancer cells found in several late-stage cancers and chronic diseases in humans. The Company is aiming to develop precision medic … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
History | Cleara Biotech Skip to content Toggle Navigation Home Company About Team Board History Business progress Contact Focus Impaired-p53 in cancer Programs Pipeline Careers Toggle Navigation Home Company About Team Board History Business progress Contact Focus Impaired-p53 in cancer Programs Pipeline Careers History Cleara Biotech B.V. was founded in order to translate academic findings to benefit patients. Some historical highlights that provided rationale for translation through Cleara include: 2008 FOXO4 and p53 can physically interact in cells. Both proteins are involved in how cells … tance work was completed and Drug Product work to a phase prior Clinicial Trial Application. 2026 onwards: Clinical trial design, application and execution Together with our 3 rd party CROs, Cleara’s senior medical and clinical team designed Phase 1a and 1b clinical trials to examine the efficacy of CL04183 in patients. While the primary readouts are safety, CL04183’s efficacy will be measured in plasma as well. This will provide a meaningful measure of efficacy in an early p
%PDF-1.4 %���� 1 0 obj > endobj 3 0 obj > endobj 4 0 obj > stream x���_�$�y ����?� ��|C�%�,R"i�+�\�&)�hϘ:4mr},TV��xl��\銾�d�����g����ݙ�%���8�"���{���*�""�y��b�;ܭ�ʌz3⍣#(@=?�x֦����7��/i�� U�G��Q}����¹HjՏ�5�����o����g폢��4? #�Ǫ80^�WT��7t%��eՏ�fU��Ւ�'6Y�=�E��Q��+I �ѢpQ����X�X}ӏ^v�(��PW ���V?��o��aEGX�V/�����g�S�� �j��h��{�U�l�� ���K��Պ��\�#ݴo��j��i� @��/�X~�V�LVU���,`�^Zݱ��cVVҒ���B��U"�[�qz��w�Z��k���v0��J���%"$* �~� �.x�T��][Rϲ�����)�ݡ3���Kk �= ���;�E�C���!���`�7͓�2��ٗ��g ���H�gE��bqȉ�!l��n0��[$�t�e���V�� �KVE���dw\�楒]�h��s�X1�l�,z��"�b@�BO��i�MP�
Teaching English in Japan: Requirements and Visa Sponsorship | STEPHEN HERBERT posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, … igh fluency, extensive experience, and strong TEFL/TESOL qualifications. How to Apply Start early, gather documents (transcripts, police cleara 3 2 Comments Like Comment Share Copy LinkedIn Facebook X RUMA SCHOOL LANGUAGE 5mo Report this comment Baba code, have Japa to Japan ? Like Reply 2 Reactions 3 Reactions To view or add a comment, sign in More Relevant Posts Embark Recruiting 220 followers 5mo Report this post E-2 Visa Process and Arrival in Korea | Complete G … right structure, it’s absolutely achievable. If you’re planning a UK move, visa application, or supporting international talent — let’s talk. 👉 www.englishpapa.com 📍 Corporate English Training | London & Online 7 5 Comments Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in ELSAA 678 followers 4mo Report this post 𝗨𝗞 𝗚𝗼𝘃𝗲𝗿𝗻𝗺𝗲𝗻𝘁 𝗥𝗲𝘃𝗶𝗲𝘄 𝗼𝗳 𝗘𝗻𝗴𝗹𝗶𝘀𝗵 𝗟𝗮𝗻𝗴𝘂𝗮𝗴𝗲 𝗔𝘀𝘀𝗲𝘀𝘀𝗺𝗲𝗻𝘁 𝗠𝗲𝘁𝗵𝗼𝗱𝘀 We welcome the UK G … other subjects. Applicant will have to be at least 16 years of age or older to apply; should have been taken that relevant course in an accredited #institution ; should have adequate money to support themselves without any dependency and likewise capable enough to pay for the return or onward journey. An under 18 applicant should also keep in mind to make proper arrangements for their travel and stay in the #UK and likewise also possess consent (in the form of a letter) of a
Business progress | Cleara Biotech Skip to content Toggle Navigation Home Company About Team Board History Business progress Contact Focus Impaired-p53 in cancer Programs Pipeline Careers Toggle Navigation Home Company About Team Board History Business progress Contact Focus Impaired-p53 in cancer Programs Pipeline Careers Business progress Business highlights 2018: Incorporation of Cleara Biotech B.V. through a joint effort by Apollo Health Ventures and dr. Peter de Keizer 2019: Cleara becomes the main industrial partner of the ZonMw/Health~Holland Public Private Initiative Voila/SMARTage 202 … o a sizeable investment by Apollo VC, Curie Capital, ROM Utrecht, LongevityTech.Fund and ISTAR Biotech B.V. 2022: Cleara becomes the main industrial partner of the ZonMw/Health~Holland Public Private Initiative TASCFORCE together with independent groups at the UMC Utrecht (Netherlands) to investigate to potential of CL04183 in (colon) cancer 2023: Successful nomination of CL04183 as Development Candidate 2023: Advice by the EMA/MEB on how preclinical development and GLP-Tox s
MoCA has... - Ministry of Civil Aviation, Government of India Facebook Log In Ministry of Civil Aviation, Government of India's Post Ministry of Civil Aviation, Government of India Verified account July 17, 2020 · Shared with Public MoCA has setup an Investment Clearance cell (ICC) for prompt assistance and clearance of proposals. Interested investors are requested to contact the officers named in the order below or call at +91 11 2465365. The MOCA order: civilaviation.gov.in www.civilaviation.gov.in All reactions: 17 2 comments Like Comment Most relevant Mohammad Hazrat When will be deci
Cleara Biotech Skip to content Toggle Navigation Home Company About Team Board History Business progress Contact Focus Impaired-p53 in cancer Programs Pipeline Careers Toggle Navigation Home Company About Team Board History Business progress Contact Focus Impaired-p53 in cancer Programs Pipeline Careers Careers Careers There are currently no job openings. We do not currently have any open positions. However, as opportunities arise, they will be posted on this page in a timely manner. Stay tuned for exciting career opportunities in the future! Copyright © Cleara Biotech | Legal Information | Da
Customs to Set up Technical Working Group to Ease Healthcare Cross-Border Clearance | Nigeria Customs Service
Cleara Biotech Skip to content Toggle Navigation Home Company About Team Board History Business progress Contact Focus Impaired-p53 in cancer Programs Pipeline Careers Toggle Navigation Home Company About Team Board History Business progress Contact Focus Impaired-p53 in cancer Programs Pipeline Careers Careers Careers There are currently no job openings. We do not currently have any open positions. However, as opportunities arise, they will be posted on this page in a timely manner. Stay tuned for exciting career opportunities in the future! Copyright © Cleara Biotech | Legal Information | Da
Cleara Biotech B.V. Asset Profile | Preqin Skip to main content Products Our products Preqin Pro Alternative assets data platform Private Markets Research Industry research Term Intelligence Benchmark LPA terms Preqin Benchmarks Industry's leading performance data Preqin Sustainability ESG data and insights Company Intelligence Companies & deals data Enterprise Data Solutions Flexible data delivery solutions Transaction Intelligence A $5.4tn transaction repository Client stories What our clients say Quick Links Our data Asset classes we cover Create a free account Newsletter Contribut … r analysis Keep up with market trends Spot new business opportunities Benchmark fund terms Navigate private credit investing Quick Links Our data Asset classes we cover Create a free account Newsletter Contribute data Contact us Insights+ Private markets research Homepage Browse reports Search Search the research library Webinar recordings Join conversations with our analysts Meet the analysts Meet the team behind the reports Learn more Learn more about Private Markets Resear … r analysis Keep up with market trends Spot new business opportunities Benchmark fund terms Navigate private credit investing Insights+ Homepage Search Webinar recordings Meet the analysts Learn more News & content Homepage Events Free Benchmarks Data coverage map Preqin Profiles Preqin Academy Compensation calculator About Who we are Our corporate responsibility Partners Press hub Careers Contact us QuickLinks Our data Asset classes we cover Create a free account Newslett … ed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers. Request demo Cleara Biotech B.V. - overview Established 2018 Location Utrecht, -, Netherlands Primary Industry Biotechnology About Based in the Netherlands, and founded in 2018, Cleara Biotech B. V. provides therapies for the treatment of different types of “senescent” cells. The company was spun out from the Medical C … Ventures with participation from other investors Curie Capital, Longevity Tech Fund, and ROM Utrecht Region. The company develops the next generation of subtype-specific anti-senescence compounds which helps in restoring tissue homeostasis. Additionally, the firm offers a FOXO4-based treatment approach that uses the biomarker and eliminates the
Dr. Ethan Shen's Vision for Integrated Oncology Ecosystem at YD Bio | YD Bio Limited posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or
About | Cleara Biotech Skip to content Toggle Navigation Home Company About Team Board History Business progress Contact Focus Impaired-p53 in cancer Programs Pipeline Careers Toggle Navigation Home Company About Team Board History Business progress Contact Focus Impaired-p53 in cancer Programs Pipeline Careers About Development of the next generation of p53-targeting therapies that are effective even when p53 is mutated. That’s our vision. Cleara Biotech’s expertise lies in understanding the molecular and biological pathways underlying modifications in the tumor suppressor protein p53 (I), ho
OTC Markets | Official site of OTCQX, OTCQB, OTCID and Pink Limited Markets You need to enable JavaScript to run this app.
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
Cleara Biotech | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Cleara Biotech Website: Cleara Biotech Business Area(s) Therapeutics Description Developing methods to clear cells Career Page(s) Careers Company Location(s) Utrecht Netherlands body Sign up for news Contact Us Add an Employer About the Site Site's Purpose and Use Articles People in Biotech
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
%PDF-1.6 %���� 5955 0 obj > endobj 5985 0 obj >/Filter/FlateDecode/ID[ ]/Index[5955 55]/Info 5954 0 R/Length 135/Prev 14976611/Root 5956 0 R/Size 6010/Type/XRef/W[1 3 1]>>stream h�bbd```b`��"��H�� �=D2%�Ha��0���z`r;X�S0�� & ��D�"���H� R� l�/��^�w�v��`��f6�lq�y�����m L� �@"@UL�gx��@��Z� endstream endobj startxref 0 %%EOF 6009 0 obj >stream hެV{TT���3�0��y N�����̀6�"�ƨ�i�D���Ԕ� 2/��|e$�֕�=S���j^_)����A Wo� ֺ����u�A�V���9k���~�o߷��sp�z �� }�=�" CDs������j��r�=btɱ�hy�Vu�;z-Z�=��DL��9jNF;�C��n��,pA�@� -ș(�������N�:��tl�8Y�b����?;c�C/��e��G�R !�b�]� 1� �0����� … �д� �[0��N����g��t�WW�0bW��WY�Mc�`�l� .U�,��]a�UTK����?ء!� >stream application/postscript Print joanne Adobe Illustrator CC 2014 (Macintosh) 2016-04-28T14:36:18-07:00 2016-04-28T14:36:18-07:00 2016-04-28T14:36:18-07:00 xmp.did:3e130ef9-4073-4312-8817-8918111b5aeb xmp.iid:3e130ef9-4073-4312-8817-8918111b5aeb uuid:15079D8A3253DD11A615D4C932A87C17 xmp.iid:c48cfa24-965f-43ef-a2d7-4bda6babeeef xmp.did:c48cfa24-965f-43ef-a2d7-4bda6babeeef uuid:15079D8A3253DD11A615D4C93 … 65f-43ef-a2d7-4bda6babeeef uuid:15079D8A3253DD11A615D4C932A87C17 converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:4ac8c5ac-4a4f-4eff-9d36-a4e33e1950eb 2015-11-06T13:06:27-08:00 Adobe Illustrator CC 2014 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrato … from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:4dbcb9d3-e5e2-4d51-b6dd-cb3acfa53533 2015-11-14T12:34-08:00 Adobe Illustrator CC 2014 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator s … 015-11-20T15:34:47-08:00 Adobe Illustrator CC 2014 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:3e130ef9-4073-4312-8817-8918111b5aeb 2016-04-28T14:36:18-07:00 Adobe Illustrator CC 2014 (Macintosh) / Print 1 False False 4.000000 4.000000 Inches Cyan Magenta Yellow Black PANTONE 363 C PANTON
--> Peter de Keizer Medical Technology 3D Printing AI in Healthcare Assistive Technology Digital Health Digital Modeling Laboratory Automation Nanotechnology in Healthcare Precision Medicine Robotic Surgery Synthetic Biology Health Antibiotic Resistance Big Pharma Cancer Diabetes Heart Disease Mental Health Musculoskeletal System Respiratory Disease Stroke Augmentation Artificial Organs Biohacking Brain Interface Exoskeleton Nootropics Prostheses Vision Life Extension Aging Research Anti-Aging Biological Age Calorie Restriction Cryonics Ethics Fountains of Youth Gene Therapy Immortal Animals I
%PDF-1.4 %���� 2453 0 obj > endobj xref 2453 28 0000000016 00000 n 0000002414 00000 n 0000002577 00000 n 0000003411 00000 n 0000004159 00000 n 0000004758 00000 n 0000004873 00000 n 0000004962 00000 n 0000005441 00000 n 0000006022 00000 n 0000006112 00000 n 0000006658 00000 n 0000007286 00000 n 0000177475 00000 n 0000342392 00000 n 0000504064 00000 n 0000656473 00000 n 0000810583 00000 n 0000961877 00000 n 0001117789 00000 n 0001267518 00000 n 0001271109 00000 n 0001275168 00000 n 0001280087 00000 n 0001280128 00000 n 0001282785 00000 n 0000002188 00000 n 0000000878 00000 n trailer ]/Prev 48276 … 0 0.000000 C=0 M=0 Y=0 K=100 CMYK PROCESS 0.000000 0.000000 0.000000 100.000000 application/postscript Vector_UMCGlang_FC MacBook_Paul proof:pdf xmp.did:1fd8e9ab-2279-44f8-8f83-dcca90b54835 xmp.iid:1fd8e9ab-2279-44f8-8f83-dcca90b54835 uuid:fd3a9920-1618-784f-9fa1-920d93843cb6 uuid:27a45ab8-a5f9-6349-97fc-3b9e0f5669e2 uuid:fd3a9920-1618-784f-9fa1-920d93843cb6 uuid:fd3a9920-1618-784f-9fa1-920d93843cb6 proof:pdf saved xmp.iid:1fd8e9ab-2279-44f8-8f83-dcca90b54835 2014-12-04T10:00 … 1D858F98770094 2009-12-01T15:12:33+01:00 Adobe Illustrator CS4 / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:74117FF120071168BB1D858F98770094 2009-12-01T15:22:25+01:00 Adobe Illustrator CS4 / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from app … t to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:A4892C2B20331168BB1D858F98770094 2009-12-01T15:42:43+01:00 Adobe Illustrator CS4 / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to app … from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:F87F117407206811B6AE90307E38C214 2010-12-10T11:29:13+01:00 Adobe Illustrator CS4 / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:FB7F117407206811B6AE90
PharmiWeb.com – Thank you 1998 – 2026 AFTER TWENTY–EIGHT YEARS Thank you. Thank you for building PharmiWeb.com Since 1998, this community has helped people find opportunities, build careers, and connect across the industry. As we close this chapter, we do so with gratitude and pride in what we created together. For everyone who found an opportunity here, from entry-level roles to VP positions , and everything in between. And for every advertiser, partner, reader, and every member of the PharmiWeb team since 1998. We were there at the beginning of the dot-com era, even beating
COSCIENS Biopharma details going-concern and key risks | CSCI SEC Filing - Form 20-F --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Cry … eding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐   Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definitions of “accelerated filer,” “large accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):   … tions and expenditure requirements; our ability to seek additional financing to fund our business activities in the future; and the plans, objectives, future outlook and financial position of the Company in general. Neither the Company’s independent auditors, nor any other independent accountants, have compiled, examined, or performed any procedures with respect to the forecasts and projections contained herein, nor have they expressed any opinion or any other form of a … lability.   If necessary, we may also seek to obtain the capital needed to fund our operations through public or private equity offerings, debt financing transactions, refinancing or restructuring its current debt obligations, or by any other means. If we are unable to obtain sufficient funding, we could be forced to delay, reduce or eliminate all of our sales efforts or to reduce or curtail operations and development activities, and our financial condition and results o … our ability to continue as a going concern. If we seek additional financing to fund our business activities in the future and there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding to us on commercially reasonable terms or at all. Addit
%PDF-1.7 %���� 1 0 obj >/Metadata 65357 0 R/ViewerPreferences 65358 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 595.32 841.92] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��W[o�H~G�?�G��_�����.PJ��6��6�Ҭ��J�������@$l�̙9߹�7g��9{���e��}�f����� p�\��l��=���4OƳ��r�=����� ��\����p����v����SDp����y�n}y�v�b�n%� #T������N(��1 ��(�����o\�e���v�6��w���n�q����9��&���PgWg)av�:���86����;M3ߥ�[7�Hg��� � nT4�/-�M4?�gD�3;=Z��R���Ԃ0RI"�4���߅����"��%ܞ����� ��� v�z@��v�.�F … ��w X`P�~�4�Y�4�8.��,� @>���j���A��WZ��s�M,�[d�z�m���&���������m���YH��RFp � �@zg�5{I��.�d�ь�Da$��)9��d�r:T���t�� kqh�� F2���� ������5����ˁ��E ����s�s6�� �յ �dxa�FH"(��2���m�8'wJ� � �ӭm�����9�xc�X1�B���Ðܨ�z�$�z��rx ��|=�총.��{&������)q=���� pG�����O�|?ԧ���v��^�� �\\\@��=��B�\ Nӎ��k��EE�zU]3T�մ�]Fط�s�=�dq�@Z��M��"�!�8���sd-+(e$���g8=kR𦷭Iy{.���AoP3�� 3�����k��5+m N���`�r��u�I$�����n���E,[�vJ�]}�= s����𨷷H�i/��#.��� ����f� … ���Bၑ�o'�.p^h����Z�[N���6� �j��m�Ւ8�}��t%�BI�k�RJ�T�#��+��}��h�c���͝ԣz�ؒL�rFp;h/VյO ��Úy�5=b-@ݙ"h-̲H�((����9$u98�4Ǐ4���s-��W1^�`�pnF%NA��9����˯ �kQ� ֖Q�,�nau@��� ��� կu�ORKiG��}1� � �,O�D`Q��2GOC@ Ƒ�+}Z����n�u UW���T8F��Y�����y8�^�b��IYf���z�v��u���+�� '��_������mk���iw(��m��o.�n,ۉ��S8�9���*�����N_5�>h��!��� �5W�# �-?�5+��-#���!�s��r1�5����KW��GmJ=Oʞ&K��əbX�d���� � � �E���$��a�V�H���x?�Z����Ũki�mv4�Q�f�Dv*IF�.��s�� ��|!��iZN�k���� … Ҁ=�h�6���g{��Q�V$ �I ~"��=�9� �;�*�[\�� �&���Xojz'� w7�1Op�n�#�+ rFp�6�V�ֱ�ZOż��9bp����Y5�&MM���,�P_�j�e � ���#��R��Ιs�4d�4l� ��x�� �x;I�eլ��⼉�� %�Q��J�,�u��@*O��[҅���S���b�sp�Z8;J��� �x�C[ųmgNO!�a7I�� �� 1�^S}-�x�O-����j1��?t�� �����l���(��ÿ����L�8�W��/�+}���BH���a���O�W�ޓ�KZ��eg$�����#/� Fi�����1$���ie���3,a��,Fk�m����k��=[H�����]ڦ�� j�@�� �7Ͽ($���^�?�u}2o�I ��b���S�C�� �l 0G�c�q$ v��o�:F����[�K쑮B(RU� ��:���3[�������չ�r95� … ���V_x�TmJ���$�Z�$7;]��}���0�i\ �hյ=R�E�'�u����7�+����'�WԼC��6���%V腷D��RFp��� s��S��^��|4�ծ�{o��5�N�l �g;~�a�2;b����`�|%�ZC ��YM ���gWXɒ �Wh��P_�j�Zŧڬ.�n(�da�YN ���W �W���~4���[���bp� @��#��ٻ���]�QEQEQE6DYch�;X8$ qҲn�m��v1�y~]���3�@ʈ����`q[��v���� �ԛOC��h�G� t� �2��n���u2x�E�B�[mF ��0a��������h����oO֒cc;3B�e
AstraZeneca at EHA2026: Blood Cancer R&D Updates | Anas Younes posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to
Podcast aflevering: 41. kankerbestrijding en biotechnologie: de unieke aanpak van cleara biotech - Samen voor een sterke Eemvallei 06 43228705 [email protected] Home Netwerk Over ons Projecten Nieuws Agenda Contact Selecteer een pagina Podcast aflevering: 41. kankerbestrijding en biotechnologie: de unieke aanpak van cleara biotech okt 8 2024 Podcast aflevering: 41.kankerbestrijding en biotechnologie: de unieke aanpak van cleara biotech Impact033, Dotslash Utrecht, Startup Utrecht Region en ROM Utrecht Region produceren gezamenlijk tweewekelijks de podcast Pepper. Podcast aflevering: 41.kanker
Our podcast explaining how Cleara Biotech B.V. progressed from a very early startup in 2018 towards advanced preclincal stage (and hopefully clinical stage in H2 2025) was ranked as the best aired of… | Cleara Biotech B.V. LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your cho
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
🎙️ Listen in as Sundeep Misra and Arup Ghosh decode: * AFI’s mandatory sponsor clearance * India’s chances at the World Relays * The future of relays in India Watch the video to know more. #indianathletics #athletics Athletics Federation of India | nnis
Hear from Our Satisfied Attendees | Bio-IT World Expo's Testimonials | May 18-20, 2026 About About the Event Attendee List Social Media Get Involved Online Learning & Podcasts Media Gallery Testimonials Key Contacts FAQ Agenda Search Agenda Event-at-a-Glance Conference Tracks Symposia Workshops FAIR Data Hackathon Plenary Keynotes Interactive Discussions Intelligence Briefs Speaker Biographies Brochures Networking Venture/Partner Event Sponsorship Attendee Demographics + Features Sponsorship Opportunities Current Sponsors Sponsorship Prospectus Current Exhibitors/Floorplan Re-sign Floo … wcase Awards Innovative Practices Awards Best of Show Awards Emerging Innovator Award Travel Press Newsroom Media Partners Press Pass Podcast Posters Poster Information Poster Titles Register Individual Pricing Group Pricing On-Demand Pricing Exhibit Hall & Keynote Pass Bio-IT World Conference & Expo Participant Testimonials 2025 "Navigating the complex landscape of R&D IT within a large pharma requires a strategic vision. Bio-IT World in Boston provided a vital f … s one of my interests and in coming here, I got so many tips which I can use to apply my studies." Christopher Egbulefu, M.D., Director at University of Texas, Dallas "The majority of the business is here. It is the right place to be. It's my first time here and this is fantastic. I would strongly recommend it to others." Flavia Guinazu, Senior Medical Advisor, University of Chile 2024 "It was an amazing fusion of innovation, R&D, drug discovery and pureplay technology th … ight have existed without speaking with these folks in person." Justin Loutsch, Application Support Mgr, inviCRO "Fantastic, as usual!" Thomas Bartlett, Head Healthcare & Life Science, DataCore "Bio-IT World provided an unmatched opportunity to learn about the challenges our industry faces and to explore potential solutions." 2022 "A festival of cutting-edge solutions in the Bio-IT domain, a perfect place for matching interests to boost computational capabilities. B
Cleara Biotech B.V. | BIO-Europe You need to enable JavaScript to run this app. This site is part of the Informa Connect Division of Informa PLC Informa PLC About Us Investor relations Talent This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. November 9–11, 2026 Koelnmesse Cologne, Germany Home home Ways to attend expand_more Registration Options Company Presentation Options Delegations Program expand_more 2026 Agenda
Team | Cleara Biotech Skip to content Toggle Navigation Home Company About Team Board History Business progress Contact Focus Impaired-p53 in cancer Programs Pipeline Careers Toggle Navigation Home Company About Team Board History Business progress Contact Focus Impaired-p53 in cancer Programs Pipeline Careers Team Management and finance Peter de Keizer, PhD Managing Director × Peter de Keizer, PhD Managing director Peter de Keizer is the founder and managing director of Cleara Biotech B.V. He has 10+ years experience in valorization, intellectual property and preclinical research and de
Board | Cleara Biotech Skip to content Toggle Navigation Home Company About Team Board History Business progress Contact Focus Impaired-p53 in cancer Programs Pipeline Careers Toggle Navigation Home Company About Team Board History Business progress Contact Focus Impaired-p53 in cancer Programs Pipeline Careers Board Supervisory Board Angelos Stergiou, MD, ScD hc Chairman of the Board × Angelos Stergiou, MD, ScD hc Chairman of the Board Dr. Angelos Stergiou has more than 20 years of biopharma experience and is the founder, President and Chief Executive Officer of SELLAS Life Sciences Gro … al investments in Cardior Pharmaceuticals and Verovaccines. She represented the fund on the Boards of preOmics and coramaze technologies. Earlier in her career Marianne worked as a management consultant and supported pharmaceutical and medtech companies relative to strategy, portfolio and business unit development. Marianne obtained a Bachelor’s and Master’s degree with distinction in Biotechnology from the RWTH Aachen University and The Scripps Research Institute, and conduc … r where she was responsible for the technology transfer of inventions and a PoC fund in biomolecular mass spectrometry & proteomics (12 investments). On consultancy/project basis she worked on a large project for (former) Organon in Oss (NL) and New Jersey (US). Close Copyright © Cleara Biotech | Legal Information | Data Privacy Copyright © Cleara Biotech Legal Information | Data Privacy Page load link This website uses cookies. See settings and read our data privacy page
CL04177 / Cleara Biotech CL04177 / Cleara Biotech - LARVOL DELTA Home Next Prev 1 to 2 Of 2 Go to page 1 March 06, 2024 Peptide-based pivoting of p53 to target metastatic breast cancer (AACR 2024) - "One of our lead compounds, CL04177 dissociates p53 from its PML scaffold leading to its a nuclear exclusion and initiation of the transcription-independent mitochondrial apoptosis...Moreover, peptides that release scarring markers from nuclear structures can eliminate aggressive cancers in vitro and, most importantly, in vivo, e.g., in p53-mutated, metastatic TNBC. This ability introduces a c … th participation from Curie Capital B.V., ROM Utrecht Region and Longevity Tech Fund. The proceeds will be used to progress Cleara’s compounds toward clinical development and further build the Company’s developmental pipeline and management team....Cleara has optimized two lead developmental candidates, CL04177 and CL04183, that can eliminate scarred cancer cells found in several late-stage cancers and chronic diseases in humans....Molecular and cellular understanding of cell
Fight Aging! Newsletter, October 24th 2022 – Fight Aging! Home FAQ Fund Research Services Investing Therapies Newsletter Archives Press Room Resources About Fight Aging! Do you want to live a longer life in good health? Simple practices can make some difference, such as exercise or calorie restriction. But over the long haul all that really matters is progress in medicine: building new classes of therapy to repair and reverse the known root causes of aging. The sooner these treatments arrive, the more lives will be saved. Find out how to help » October 23rd, 2022 Fight Aging! Newsl … h participation from Curie Capital B.V., ROM Utrecht Region, and Longevity Tech Fund. Cleara has optimized two lead developmental candidates, CL04177 and CL04183, that can eliminate scarred cancer cells found in several late-stage cancers and chronic diseases in humans. The company is aiming to develop precision medicine tools that treat specific diseases with clear niche-directed, anti-senescent lead candidates, accompanied with associated biomarkers, around its FOXO4-based … ane, CML, and other cross-links involved in aging, and that remains the initial application of their platform. This is an early stage effort, and they have not yet tested candidate molecules in animals. They intend to raise a series A next year. Hans S. Keirstead outlined work under way at Immunis, one of the more advanced of the companies presenting at the event. They harvest the secretome of carefully tailored progenitor cell lines, and package those molecules as a therapeu … net worth individuals to large holding companies. Venture partners running the fund are the industry experts, while the limited partners tend to know a lot less about the markets that they invest in. They are, in effect, hiring the fund to manage this opportunity. However, venture funds exist in a competitive marketplace for limited partner funds, and limited partners are primarily interested in financial outcomes rather than changing the world. Thus we see that all too many … rent hype for longevity in order to obtain limited partner investment, and then fund projects that are prioritized by how likely they are to keep the limited partners happy with the bottom line at the end of the day. Unfortunately, a safe project in this context usually means that it is unambitious and unlikely to greatly affect the bottom line o
Cleara Biotech closes $2.5M round for senescence treatment Skip to content Search for: Suggested Topics: Categories Browse by resource or article category Knowledge hub Resources Biotech funding tracker Biotech deals tracker Biotech layoff tracker Biotech events 2026 List of biotech grants Biotech associations Categories News and Trends In-depth Best in Biotech Podcasts Top Pharma Strategy Opinion Expert Advice Sponsored Mending university and venture capital relations: is it possible to see eye-to-eye? Portugal: will the life science sector see upswing amid funding worries? Sectors Browse by … th participation from Curie Capital B.V., ROM Utrecht Region and Longevity Tech Fund. As well as progressing compounds, Cleara Biotech will also use the money to further build its developmental pipeline and management team. Scarred cancer cells Cleara Biotech has optimized two lead developmental candidates, CL04177 and CL04183, that can eliminate scarred cancer cells found in several late-stage cancers and chronic diseases in humans. Cleara Biotech is aiming to develop precis
Cleara Biotech Skip to content Toggle Navigation Home Company About Team Board History Business progress Contact Focus Impaired-p53 in cancer Programs Pipeline Careers Toggle Navigation Home Company About Team Board History Business progress Contact Focus Impaired-p53 in cancer Programs Pipeline Careers Home Improving lives through peptide-based clearance of p53-impaired cells. That’s our mission Cleara Biotech is a biopharmaceutical research and development (R&D) company focused on developing peptide-based therapies against cancer and chronic diseases. Our lead program focuses on generati
Longevity Investors Investing in Anti-Aging Biotech Startups Blog Fundraising Due diligence Data room M&A Startups Log in Get demo Start a trial Blog / Fundraising Longevity investors investing in anti-aging biotech in 2026 9 December 2025 · 14 min read Author Ellty editorial team Longevity went from fringe science to serious biotech in three years. Most investors still confuse healthspan extension with wellness apps. The ones on this list actually funded companies through Phase 2 trials and understand the difference between rapamycin analogs and NAD+ supplements. Quick list Longevity Visi … nce between rapamycin analogs and NAD+ supplements. Quick list Longevity Vision Fund : Led Altos Labs' $3B raise for cellular reprogramming in 2024. Khosla Ventures : Backed NewLimit's $105M Series A for epigenetic reprogramming in 2025. Andreessen Horowitz : Led Loyal's $58M Series B for dog aging drugs in 2024. Juvenescence : Invested $45M in Cleara Biotech for senescent cell clearance in 2025. Apollo Health Ventures : Backed Shift Bioscience's $23M Series A … acked Selphagy's $18M Series A for autophagy enhancement in 2025. Longevity Fund : Led Repair Biotechnologies' $12M Series A for thymus regeneration in 2024. 8VC : Invested $90M in Retro Biosciences for autophagy and plasma therapies in 2025. Methuselah Fund : Backed LyGenesis' $100M Series B for organ regeneration in 2024. Kizoo Technology Capital : Led Oisin Biotechnologies' $20M Series A for senolytic gene therapy in 2025. Jim Mellon's Juvenescence : In … Cradle Genomics' $22M Series A for induced tissue regeneration in 2025. OS Fund : Invested in Oisin Biotechnologies' senolytic platform development in 2024. Picking investors who understand longevity science Experience : Find investors who've backed biotech through clinical trials, not just preclinical hype. Ask their portfolio companies about support during Phase 2 failures. Most longevity startups pivot their lead indication three times before finding something … nize due diligence : Set up an Ellty data room with your animal study data, IND application drafts, and scientific publications before they ask. It speeds up the process when they want their scientific advisors to review your mechanism. Set up introductory meetings : Lead with your efficacy data in animal models and your FDA strategy. Don't w